The CE Mark represents Sphere Medical's transition from a promising technology platform into a commercial organisation. The initial launches of Proxima 4 across major European markets are expected before end-2016. Gaining meaningful sales traction will require well-connected local marketing partners. An Italian distributor is already in place and additional partnerships are expected during the coming year. The reduction in investment risk sees our three-phase DCF-based model valuation increase from our previous £21.8m, equivalent to 15.4p a share, to £30.2m, equivalent to 21.3p per share.
30 Sep 2016
CE Mark opens the door to commercialisation
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
CE Mark opens the door to commercialisation
Sphere Medical Holding (SPHR:LON) | 0 0 0.0% | Mkt Cap: 0.037m
- Published:
30 Sep 2016 -
Author:
Franc Gregori -
Pages:
9
The CE Mark represents Sphere Medical's transition from a promising technology platform into a commercial organisation. The initial launches of Proxima 4 across major European markets are expected before end-2016. Gaining meaningful sales traction will require well-connected local marketing partners. An Italian distributor is already in place and additional partnerships are expected during the coming year. The reduction in investment risk sees our three-phase DCF-based model valuation increase from our previous £21.8m, equivalent to 15.4p a share, to £30.2m, equivalent to 21.3p per share.